Symptoms of Selective IgA Deficiency (SIGAD)
Many patients with SIGAD are completely asymptomatic, but symptomatic patients most commonly present with recurrent sinopulmonary infections (pneumonia, sinusitis, otitis media), followed by allergic diseases (asthma, allergic rhinitis, atopic dermatitis), autoimmune conditions, and gastrointestinal disorders. 1
Clinical Presentation Spectrum
The clinical manifestations of SIGAD follow a characteristic natural progression, typically beginning with infectious diseases, followed by allergic manifestations, and later autoimmune conditions 2. Understanding this sequence is critical for anticipating complications over time.
Infectious Manifestations (Most Common)
Recurrent sinopulmonary infections are the hallmark presentation:
- Pneumonia (occurs in 94% of symptomatic patients) 3
- Sinusitis (70% of cases) 3
- Recurrent otitis media (11.8% develop recurrent ear infections, with 2% progressing to secondary deafness) 3
- Bronchiectasis as a complication in 6% of patients with recurrent pneumonia 3
- Gastrointestinal infections, particularly with Giardia lamblia 4
The evidence shows that 98% of symptomatic pediatric patients present with infections as their primary manifestation 2.
Allergic Diseases (Second Most Common)
Atopic manifestations occur frequently in 66.7-92% of patients 5, 2:
- Allergic rhinitis
- Asthma
- Atopic dermatitis
The guidelines emphasize that allergic inflammation predisposes to respiratory tract infections, creating a vicious cycle that requires aggressive treatment 1. Patients with allergic sensitization show significantly elevated total IgE levels and eosinophilia 6.
Autoimmune Disorders
Autoimmune diseases affect 11.5-13.3% of patients 3, 5:
- Thyroid disease (most common - 60% of autoimmune cases): Hashimoto's thyroiditis, hyperthyroidism, hypothyroidism 3, 7
- Type 1 diabetes mellitus 7
- Celiac disease (6.6% of patients) 3
- Juvenile idiopathic arthritis/rheumatoid arthritis 7
- Systemic lupus erythematosus 4, 7
- Inflammatory bowel disease (Crohn's disease, ulcerative colitis) 7
- Vitiligo 7
- Cytopenias (immune thrombocytopenic purpura, autoimmune hemolytic anemia) 3, 7
Importantly, elevated IgM or IgG levels (hypergammaglobulinemia) are significantly associated with autoimmune conditions or presence of autoantibodies 2.
Gastrointestinal Manifestations
Malignancy
Tumors occur in 1.5% of patients, representing a rare but serious complication 3.
Important Clinical Caveats
Asymptomatic Presentation
The majority of individuals with SIGAD are asymptomatic and lead normal lives 8, 4, 7. This creates a diagnostic challenge, as many cases are only discovered incidentally during blood donation screening or after transfusion reactions 9.
Transfusion Reactions
Patients with complete IgA deficiency may develop anti-IgA IgE antibodies, creating risk for anaphylactic reactions to blood products containing IgA 1, 4, 9. While the individual risk is likely small, febrile non-hemolytic transfusion reactions can occur 9.
Progression to More Severe Immunodeficiency
Some patients with SIGAD develop Common Variable Immunodeficiency (CVID) later in life 1. Additionally, 4% develop IgG subclass deficiency, and some develop confirmed antibody production defects 3. This underscores the need for long-term monitoring.
Drug-Induced SIGAD
SIGAD can be acquired from medications including phenytoin, carbamazepine, valproic acid, zonisamide, sulfasalazine, gold, penicillamine, hydroxychloroquine, and NSAIDs 1. This is often reversible with drug cessation, making medication history essential 1.
Key Diagnostic Considerations
The diagnosis requires:
- Age >4 years
- Serum IgA <7 mg/dL
- Normal IgG and IgM levels
- Exclusion of other causes of hypogammaglobulinemia 1
T-cell populations and function remain normal in SIGAD 1, distinguishing it from combined immunodeficiencies.
Clinical Monitoring Implications
Given the natural history showing progression from infections → allergies → autoimmunity 2, patients require:
- Vigilant monitoring for development of autoimmune conditions over time
- Aggressive treatment of atopic disease to prevent secondary infections 1
- Assessment for IgG subclass deficiency or antibody production defects in patients with severe/recurrent infections
- Monitoring of other immunoglobulin levels as potential biomarkers for autoimmune risk 2